RY 151.2 -0.6636% TD 80.12 0.9577% SHOP 83.0 1.3802% CNR 158.42 -0.9751% ENB 50.51 0.0198% CP 113.01 0.9108% BMO 119.55 0.3357% TRI 227.18 0.6334% CNQ 47.185 -0.851% BN 64.45 1.7524% ATD 82.17 -0.8208% CSU 4335.0 0.7153% BNS 62.975 -0.3402% CM 69.78 0.7508% SU 53.02 0.9136% TRP 57.81 1.1018% NGT 63.51 -3.5535% WCN 241.16 -2.9029% MFC 35.73 0.7614% BCE 45.805 0.0546%
Last update at 2024-07-24T13:30:00Z
| Breakdown | 2022-02-28 | 2021-02-28 | 2020-02-29 | 2019-02-28 | 2018-02-28 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-02-28 | 2021-02-28 | 2020-02-29 | 2019-02-28 | 2018-02-28 |
| Income before tax | -2.96009M | 0.70M | -4.05642M | -3.47341M | -5.30794M |
| Minority interest | - | - | - | - | - |
| Net income | -2.96009M | 0.70M | -4.05642M | -3.47341M | -5.30794M |
| Selling general administrative | 2.41M | 2.57M | 3.17M | 4.31M | 4.45M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | - | - | 0.61M | 1.41M | 0.12M |
| Reconciled depreciation | 0.05M | 0.06M | 0.07M | 0.07M | 0.06M |
| Ebit | -3.59678M | 0.38M | -4.60168M | -4.85717M | -5.27725M |
| Ebitda | -3.54186M | 0.33M | -4.53092M | -4.78518M | -5.21837M |
| Depreciation and amortization | - | - | - | - | - |
| Non operating income net other | - | - | - | - | - |
| Operating income | -3.59678M | 0.27M | -4.60168M | -4.85717M | -5.27725M |
| Other operating expenses | - | - | - | - | - |
| Interest expense | 0.00000M | 0.00000M | 0.00000M | 0.00000M | 0.00000M |
| Tax provision | - | - | - | - | - |
| Interest income | - | - | - | 0.00178M | 0.01M |
| Net interest income | -0.65421M | -0.03585M | -0.04690M | 0.00178M | 0.01M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | - | - | - | - | 0.00000M |
| Total revenue | 0.04M | 4.08M | 0.61M | 1.42M | 0.59M |
| Total operating expenses | 3.63M | 3.81M | 5.21M | 6.28M | 5.87M |
| Cost of revenue | - | - | 0.00000M | 0.01M | 0.47M |
| Total other income expense net | 1.29M | 0.46M | 0.59M | 1.38M | -0.04204M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -2.96009M | 0.70M | -4.05642M | -3.47341M | -5.30794M |
| Net income applicable to common shares | -2.96009M | 0.70M | -4.05642M | -3.47341M | -5.30794M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-02-28 | 2021-02-28 | 2020-02-29 | 2019-02-28 | 2018-02-28 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-02-28 | 2021-02-28 | 2020-02-29 | 2019-02-28 | 2018-02-28 |
| Total assets | 2.27M | 3.28M | 0.94M | 1.74M | 1.22M |
| Intangible assets | 0.16M | 0.21M | 0.27M | 0.33M | 0.39M |
| Earning assets | - | - | - | - | - |
| Other current assets | - | - | - | - | - |
| Total liab | 4.18M | 2.87M | 3.43M | 2.29M | 0.79M |
| Total stockholder equity | -1.91736M | 0.41M | -2.48628M | -0.54666M | 0.43M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | - | - | - | 0.26M | - |
| Common stock | 27.45M | 27.26M | 25.42M | 24.20M | 22.79M |
| Capital stock | 27.45M | 27.26M | 25.42M | 24.20M | - |
| Retained earnings | -40.65397M | -37.69387M | -38.39229M | -34.33586M | -30.86245M |
| Other liab | 0.79M | 0.91M | 0.43M | 1.03M | - |
| Good will | - | - | - | - | - |
| Other assets | - | - | - | - | - |
| Cash | 1.73M | 2.74M | 0.58M | 1.36M | 0.68M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 2.99M | 1.90M | 2.48M | 1.26M | 0.79M |
| Current deferred revenue | - | - | - | - | - |
| Net debt | 0.17M | - | 0.43M | - | - |
| Short term debt | - | - | - | - | - |
| Short long term debt | 1.50M | 0.06M | 0.49M | - | - |
| Short long term debt total | - | - | - | - | - |
| Other stockholder equity | 0.18M | 0.19M | 0.02M | 0.03M | 0.03M |
| Property plant equipment | 0.00022M | 0.00464M | 0.02M | 0.03M | 0.04M |
| Total current assets | 2.11M | 3.06M | 0.65M | 1.38M | 0.79M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | -2.07632M | 0.19M | -2.75533M | -0.87448M | 0.05M |
| Short term investments | - | - | - | - | - |
| Net receivables | 0.10M | 0.03M | 0.01M | 0.00971M | 0.03M |
| Long term debt | 0.40M | 0.06M | 0.52M | - | - |
| Inventory | - | - | - | - | - |
| Accounts payable | 1.49M | 1.84M | 1.99M | 1.00M | 0.79M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | - | - | - | - | - |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | - | - | - | 0.36M | 0.43M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 0.16M | 0.22M | 0.29M | 0.36M | 0.43M |
| Capital lease obligations | - | - | - | - | - |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2022-02-28 | 2021-02-28 | 2020-02-29 | 2019-02-28 | 2018-02-28 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-02-28 | 2021-02-28 | 2020-02-29 | 2019-02-28 | 2018-02-28 |
| Investments | 0.00000M | 0.00697M | 0.00000M | 0.39M | -0.10771M |
| Change to liabilities | -0.51303M | 0.01M | 0.74M | 0.48M | 0.04M |
| Total cashflows from investing activities | - | 0.00697M | 0.00697M | 0.39M | -0.10771M |
| Net borrowings | 2.53M | -0.57596M | 1.29M | 1.29M | 1.29M |
| Total cash from financing activities | 2.64M | 0.31M | 2.49M | 3.53M | 3.90M |
| Change to operating activities | 0.18M | -0.24280M | -0.04933M | 0.07M | 0.04M |
| Net income | -2.96009M | 0.70M | -4.05642M | -3.47341M | -5.30794M |
| Change in cash | -1.00597M | 2.16M | -0.78367M | 0.68M | 0.12M |
| Begin period cash flow | 2.74M | 0.58M | 1.36M | 0.68M | 0.55M |
| End period cash flow | 1.73M | 2.74M | 0.58M | 1.36M | 0.68M |
| Total cash from operating activities | -3.63551M | 1.77M | -3.29865M | -3.22967M | -3.67314M |
| Issuance of capital stock | 0.20M | 0.19M | 1.21M | 3.53M | - |
| Depreciation | 0.05M | 0.06M | 0.07M | 0.07M | 0.06M |
| Other cashflows from investing activities | - | - | - | - | - |
| Dividends paid | - | - | - | - | - |
| Change to inventory | - | - | - | - | - |
| Change to account receivables | -0.06704M | -0.01691M | -0.00366M | 0.02M | 0.02M |
| Sale purchase of stock | - | - | - | - | 3.90M |
| Other cashflows from financing activities | -0.09043M | -0.09043M | -0.09043M | -0.09043M | - |
| Change to netincome | -0.98314M | 1.15M | -0.05884M | -0.39663M | 1.47M |
| Capital expenditures | 0.00000M | 0.00000M | 0.00000M | 0.00206M | 0.04M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | -0.40170M | -0.24753M | 0.69M | 0.57M | 0.10M |
| Stock based compensation | 0.44M | 0.28M | 0.57M | 0.98M | - |
| Other non cash items | 0.65M | 0.11M | 0.05M | - | - |
| Free cash flow | -3.63551M | 1.77M | -3.29865M | -3.23174M | -3.78085M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (CAD) | Price (CAD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| BTI biOasis Technologies Inc |
-1.17 99.57% | 0.005 | - | - | 1.47 | 54.04 | 9.11 | -0.7845 |
| NGEN NervGen Pharma Corp |
-0.05 1.71% | 2.87 | - | - | - | 29.48 | -6.9477 | |
| ARCH Arch Biopartners Inc |
-0.03 1.99% | 1.48 | - | - | 37.82 | - | 53.05 | -28.1027 |
| MIR MedMira Inc |
- -% | 0.08 | - | - | 170.46 | - | 189.94 | -48.7372 |
| TTI Thiogenesis Therapeutics Corp. |
-0.04 5.06% | 0.75 | - | - | - | 11.86 | -163.0787 |
Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing xB3, a platform technology for the transport of therapeutic agents across the blood-brain barrier (BBB); and the treatment of central nervous system disorders (CNS), including brain cancers, and metabolic and neurodegenerative diseases. The company's in-house development programs develop symptomatic and disease-modifying treatments for brain metastases (xB3-001), glioblastoma (xB3-002), and neurodegenerative diseases (xB3-007). It has research collaborations with Aposense Limited to focus on the delivery of siRNA therapeutics for CNS disorders; Oxyrane UK Ltd. to focus on combining xB3 technology and Oxyrane's OxyCAT platform to deliver an undisclosed enhanced enzyme replacement therapy into the brain; and Janssen Biotech, Inc. to research, develop, and commercialize novel products based on Bioasis' xB3 platform. The company also has a research collaboration and license agreement with Neuramedy Co Ltd. to research, develop, and commercialize an xB3TM version of its antibody, Tomaralimab. Bioasis Technologies Inc. was incorporated in 2006 and is headquartered in New Haven, Connecticut.
157 Church Street, New Haven, CT, United States, 06510
| Name | Title | Year Born |
|---|---|---|
| Dr. Deborah Ann Rathjen B.Sc. (Hons.), FTSE, M.A.I.C.D., Ph.D., Q.C. | Exec. Chairman, CEO & Pres | 1958 |
| Mr. Dave Jenkins | Chief Financial Officer | NA |
| Mr. Graeme Dick | Director of Investor Relations | NA |
| Mr. Kim Elton | Director of Marketing | NA |
| Mr. Doug Williams MBA | Exec. VP & Chief Bus. Officer | NA |
| Dr. Mei Mei Tian | VP & Head of External Research | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
CA 
AU
UK
US
NZ
Please wait processing your request...